Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;131(23):e153662.
doi: 10.1172/JCI153662.

SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women

Adeel A Butt  1   2   3 , Hiam Chemaitelly  3 , Abdullatif Al Khal  1 , Peter V Coyle  1 , Huda Saleh  1 , Anvar H Kaleeckal  1 , Ali Nizar Latif  1 , Roberto Bertollini  4 , Abdul-Badi Abou-Samra  1 , Laith J Abu-Raddad  3
Affiliations

SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women

Adeel A Butt et al. J Clin Invest. .

Abstract

BackgroundSARS-CoV-2 infection in pregnancy is associated with a higher risk of pregnancy-related complications and neonatal respiratory distress and hospitalization. Effectiveness of SARS-CoV-2 vaccines in pregnant women is not known.MethodsAll women with confirmed pregnancy who presented to the national referral hospital in Qatar between December 20, 2020, and May 30, 2021, with at least 1 SARS-CoV-2 test and not testing prior to pregnancy were included. We determined the vaccine effectiveness of mRNA vaccines in preventing confirmed SARS-CoV-2 infection during pregnancy using both cohort and test-negative case-control designs. Analyses were adjusted for age group, nationality, and gestational age.ResultsAmong 4534 pregnant women, there were 407 vaccinated and 407 unvaccinated women in the matched cohort analysis. Vaccine effectiveness was 87.6% (95%CI 44.1%-97.2%) at least 14 days after the second dose. There were 386 test-positive and 834 matched women in the test-negative case control analysis. Vaccine effectiveness was 86.8% (95%CI 47.5%-98.5%) at least 14 days after the second dose. Adjustment for age, nationality, and gestational age yielded similar results for both designs. In the test-negative analysis, vaccine effectiveness at least 14 days after the first dose but before the second dose was 40.8% (95% CI 0.0%-80.4%). Of the 386 test-positive pregnant women, 74 cases were Alpha variant, 163 cases were Beta variant, and 156 cases were variants of unknown status. There were 9 severe or critical disease cases and no deaths in the test-positive pregnant women, all of whom were unvaccinated.ConclusionThe mRNA vaccines provide a high level of protection against documented SARS-CoV-2 infection, which supports the inclusion of pregnant women in vaccination campaigns.FUNDINGHamad Medical Corporation, Weill Cornell Medicine Qatar, and the Ministry of Public Health Qatar.

Keywords: COVID-19; Epidemiology; Infectious disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: AAB received investigator-initiated grant funding from Gilead Sciences.

Figures

Figure 1
Figure 1. Flowchart of data set creation for the cohort design.
Figure 2
Figure 2. Flowchart of data set creation for the test-negative case control design.
Figure 3
Figure 3. Kaplan-Meier curves showing the incidence of infection in the matched cohorts of vaccinated and unvaccinated pregnant women.
See this image and copyright information in PMC

References

    1. Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Dagan N, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423. doi: 10.1056/NEJMoa2101765. - DOI - PMC - PubMed
    1. Abu-Raddad LJ, et al. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385(2):187–189. doi: 10.1056/NEJMc2104974. - DOI - PMC - PubMed
    1. Crovetto F, et al. Seroprevalence and presentation of SARS-CoV-2 in pregnancy. Lancet. 2020;396(10250):530–531. doi: 10.1016/S0140-6736(20)31714-1. - DOI - PMC - PubMed

Publication types

MeSH terms